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Methotrexate is the first line of treatment of rheumatoid arthritis. Since many patients 
become unresponsive to methotrexate treatment, only very expensive biological therapies are 
effective and increased methotrexate tolerance strategies need to be identified. In a previous 
European project NANOFOL, we performed the encapsulation of methotrexate in a new 
liposomal formulation using a hydrophobic fragment of surfactant protein conjugated to a 
linker and folate to enhance their tolerance and efficacy. We evaluate the efficiency of this 
system to treat rheumatoid arthritis, by targeting folate receptor β present at the surface of 
activated macrophages, key effector cells in this pathology. The specificity of our liposomal 
formulation to target folate receptor β was investigated both in vitro as in vivo using a mouse 
model of arthritis (collagen-induced arthritis in DBA/1J mice strain). In both systems, the 
liposomal constructs were shown to be highly specific and efficient in targeting folate receptor 
β. These liposomal formulations also significantly increase the clinical benefit of the 
encapsulated methotrexate in vivo in arthritic mice. A new project, called FOLSMART, will 
perform the preclinical development and the phase I clinical trials of this new liposomal 
formulation. 
